featured
Avelumab vs Physician's Choice of Chemotherapy as Third-Line Treatment in Advanced Gastric or Gastroesophageal Junction Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Annals of Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Phase 3, Randomised Trial of Avelumab Versus Physician's Choice of Chemotherapy as Third-Line Treatment for Patients With Advanced Gastric or Gastro-Oesophageal Junction Cancer: Primary Analysis of JAVELIN Gastric 300
Ann. Oncol 2018 Jul 24;[EPub Ahead of Print], YJ Bang, EY Ruiz, E Van Cutsem, KW Lee, L Wyrwicz, M Schenker, M Alsina, MH Ryu, HC Chung, L Evesque, SE Al-Batran, SH Park, M Lichinitser, N Boku, MH Moehler, J Hong, H Xiong, R Hallwachs, I Conti, J TaiebFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.